Infection with Porcine Reproductive and Respiratory Syndrome Virus and Streptococcus suis changes the pharmacokinetics of ceftiofur hydrochloride in swine

Day, D. N.

doi:10.31274/etd-180810-1679

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PRRSv challenge inoculum was prepared as previously reported (Day, ). Briefly, PRRSv isolate VR‐2385 was initially recovered from a sow herd in southwestern Iowa that experienced severe respiratory diseases in 3‐ to 16‐week‐old pigs and late‐term abortions in 1991 (Halbur et al ., ).…”

Section: Methodsmentioning

confidence: 99%

Vaccination mitigates the impact of PRRSv infection on the pharmacokinetics of ceftiofur crystalline‐free acid in pigs

Sparks

Karriker

Day

et al. 2016

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The pharmacokinetics of intramuscularly administered ceftiofur crystalline-free acid (CCFA) were determined in pigs that were clinically healthy (n = 8), vaccinated with a Porcine reproductive and respiratory syndrome modified live virus (PRRS MLV) (n = 10), challenged with wild-type porcine reproductive and respiratory syndrome virus (PRRSv) VR-2385 (n = 10), or vaccinated with PRRS MLV and later challenged with wild-type PRRSv VR-2385 (n = 10). Animals were given a single dose of CCFA intramuscularly at 5 mg/kg body weight. Blood was collected at 0 (pretreatment), 0.25, 0.5, 1, 6, 12, 24, 48, 96, 144, 192, and 240 h postinjection. Plasma was analyzed using liquid chromatography-mass spectrometry. Plasma concentration-time curves for each group were evaluated with noncompartmental modeling. When compared to control animals, those receiving the PRRSv wild-type challenge only had a lower AUC , higher Cl/F, and higher Vz/F. The PRRSv wild-type challenge only group had the longest T . The C did not differ among all four treatments. Control animals had no statistically significant differences from animals vaccinated with PRRS MLV alone or animals vaccinated with PRRS MLV and later challenged with wild-type PRRSv. Our results suggest that PRRSv wild-type infection has the potential to alter CCFA pharmacokinetics and PRRS MLV vaccination may attenuate those changes.

show abstract

Section: Methodsmentioning

confidence: 99%

Vaccination mitigates the impact of PRRSv infection on the pharmacokinetics of ceftiofur crystalline‐free acid in pigs

Sparks

Karriker

Day

et al. 2016

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…They did not find any difference between control and challenged pigs. Others have suggested the concept of pharmacokinetic changes being resultant of disease influenced vasculature pH, but there is no original research or referencing (Zeng and Fung, 1990;Agerso et al, 1998;Day, 2014).…”

Section: Vascular Permeability Flow and Phmentioning

confidence: 99%

Pharmacokinetics of ceftiofur crystalline free acid in pigs vaccinated against, challenged with, or vaccinated against and challenged with PRRSv

Sparks

View full text Add to dashboard Cite

The pharmacokinetics of intramuscularly administered ceftiofur crystalline free acid (CCFA) were determined in pigs that were clinically healthy, vaccinated with a PRRS MLV, challenged with wild-type PRRSv VR-2385, or vaccinated with PRRS MLV and later challenged with wild-type PRRSv VR-2385. Animals were given a single dose intramuscularly at 5mg/kg bodyweight. Blood was collected at 0 (pre-treatment), 0.25, 0.5, 1, 6, 12, 24, 48, 96, 144, 192, and 240 hours post injection. Plasma was analyzed using liquid chromatography-mass spectrometry. Plasma concentration-time curves for each group were evaluated with noncompartmental modeling. Vaccination and challenge models were confirmed with strain specific RT-PCRs performed on lung or tonsil tissue. When compared to control animals, those receiving the PRRSv wild-type challenge had a lower AUC 0-last , higher Cl/F, and higher Vz/F. Control animals had no statistically significant differences from animals vaccinated with PRRS MLV alone or animals vaccinated with PRRS MLV and later challenged with wild-type PRRSv.Vaccination with PRRS MLV does not change the pharmacokinetics of CCFA, and our results suggest that when faced with wild-type PRRSv challenge, vaccination with PRRS MLV preserves pharmacokinetics of CCFA.

show abstract

Infection with Porcine Reproductive and Respiratory Syndrome Virus and Streptococcus suis changes the pharmacokinetics of ceftiofur hydrochloride in swine

Cited by 2 publications

References 29 publications

Vaccination mitigates the impact of PRRSv infection on the pharmacokinetics of ceftiofur crystalline‐free acid in pigs

Vaccination mitigates the impact of PRRSv infection on the pharmacokinetics of ceftiofur crystalline‐free acid in pigs

Pharmacokinetics of ceftiofur crystalline free acid in pigs vaccinated against, challenged with, or vaccinated against and challenged with PRRSv

Contact Info

Product

Resources

About